Mer­ck touts topline PhI­II Keytru­da da­ta in pre-surgery breast can­cer treat­ment

Mer­ck’s block­buster an­ti-PD-1 ther­a­py Keytru­da is inch­ing its way to­ward an­oth­er po­ten­tial in­di­ca­tion, this time a chemother­a­py com­bo pre-surgery in pa­tients with high-risk, ear­ly-stage ER+/HER2- breast can­cer.

While Mer­ck did not share spe­cif­ic da­ta from its in­ter­im analy­sis of its Phase III KEYNOTE-756 tri­al, the phar­ma said the drug com­bo hit one of the dual pri­ma­ry end­points: show­ing a “sta­tis­ti­cal­ly sig­nif­i­cant im­prove­ment” in patho­log­i­cal com­plete re­sponse (pCR) rate com­pared to a place­bo plus chemo in the 1,240-pa­tient tri­al. A pCR is “a lack of all signs of can­cer” fol­low­ing neoad­ju­vant ther­a­py and surgery.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER